Cytosorbents (NASDAQ:CTSO – Get Free Report) released its quarterly earnings data on Monday. The medical research company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.04, Zacks reports. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The company had revenue of $9.20 million for the quarter, compared to the consensus estimate of $10.09 million.
Cytosorbents Stock Performance
Shares of CTSO stock opened at $1.00 on Wednesday. The business’s fifty day simple moving average is $1.07 and its 200-day simple moving average is $1.05. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $1.61. The company has a market cap of $54.68 million, a PE ratio of -2.78 and a beta of 0.78. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06.
Analyst Ratings Changes
CTSO has been the topic of several recent research reports. D. Boral Capital reiterated a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a report on Tuesday. StockNews.com assumed coverage on shares of Cytosorbents in a report on Wednesday, March 26th. They set a “hold” rating on the stock. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $4.67.
Cytosorbents Company Profile
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
See Also
- Five stocks we like better than Cytosorbents
- What Are Growth Stocks and Investing in Them
- Will 2025 Be the Year the Energy Sector Finally Breaks Out?
- Most Volatile Stocks, What Investors Need to Know
- NextEra Energy Stock Sees Spike in Bullish Call Activity
- What is a Low P/E Ratio and What Does it Tell Investors?
- Top 3 Stocks Mega Investors Are Buying Now
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.
